These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 34096321)

  • 1. Danicamtiv Enhances Systolic Function and Frank-Starling Behavior at Minimal Diastolic Cost in Engineered Human Myocardium.
    Shen S; Sewanan LR; Jacoby DL; Campbell SG
    J Am Heart Assoc; 2021 Jun; 10(12):e020860. PubMed ID: 34096321
    [No Abstract]   [Full Text] [Related]  

  • 2. Comprehensive analyses of the inotropic compound omecamtiv mecarbil in rat and human cardiac preparations.
    Rhoden A; Schulze T; Pietsch N; Christ T; Hansen A; Eschenhagen T
    Am J Physiol Heart Circ Physiol; 2022 Mar; 322(3):H373-H385. PubMed ID: 35030072
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A myosin activator improves actin assembly and sarcomere function of human-induced pluripotent stem cell-derived cardiomyocytes with a troponin T point mutation.
    Broughton KM; Li J; Sarmah E; Warren CM; Lin YH; Henze MP; Sanchez-Freire V; Solaro RJ; Russell B
    Am J Physiol Heart Circ Physiol; 2016 Jul; 311(1):H107-17. PubMed ID: 27199119
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Omecamtiv mecarbil evokes diastolic dysfunction and leads to periodic electromechanical alternans.
    Fülöp GÁ; Oláh A; Csipo T; Kovács Á; Pórszász R; Veress R; Horváth B; Nagy L; Bódi B; Fagyas M; Helgadottir SL; Bánhegyi V; Juhász B; Bombicz M; Priksz D; Nanasi P; Merkely B; Édes I; Csanádi Z; Papp Z; Radovits T; Tóth A
    Basic Res Cardiol; 2021 Apr; 116(1):24. PubMed ID: 33844095
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Myosin Activator Omecamtiv Mecarbil Increases Myocardial Oxygen Consumption and Impairs Cardiac Efficiency Mediated by Resting Myosin ATPase Activity.
    Bakkehaug JP; Kildal AB; Engstad ET; Boardman N; Næsheim T; Rønning L; Aasum E; Larsen TS; Myrmel T; How OJ
    Circ Heart Fail; 2015 Jul; 8(4):766-75. PubMed ID: 26025342
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mavacamten preserves length-dependent contractility and improves diastolic function in human engineered heart tissue.
    Sewanan LR; Shen S; Campbell SG
    Am J Physiol Heart Circ Physiol; 2021 Mar; 320(3):H1112-H1123. PubMed ID: 33449850
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dose-Dependent Effects of the Myosin Activator Omecamtiv Mecarbil on Cross-Bridge Behavior and Force Generation in Failing Human Myocardium.
    Mamidi R; Li J; Gresham KS; Verma S; Doh CY; Li A; Lal S; Dos Remedios CG; Stelzer JE
    Circ Heart Fail; 2017 Oct; 10(10):. PubMed ID: 29030372
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evidence for synergy between sarcomeres and fibroblasts in an in vitro model of myocardial reverse remodeling.
    Shen S; Sewanan LR; Campbell SG
    J Mol Cell Cardiol; 2021 Sep; 158():11-25. PubMed ID: 33992697
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Omecamtiv mecarbil: a new cardiac myosin activator for the treatment of heart failure.
    Liu LC; Dorhout B; van der Meer P; Teerlink JR; Voors AA
    Expert Opin Investig Drugs; 2016; 25(1):117-27. PubMed ID: 26587768
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cardiac Myosin Activation with Omecamtiv Mecarbil in Systolic Heart Failure.
    Teerlink JR; Diaz R; Felker GM; McMurray JJV; Metra M; Solomon SD; Adams KF; Anand I; Arias-Mendoza A; Biering-Sørensen T; Böhm M; Bonderman D; Cleland JGF; Corbalan R; Crespo-Leiro MG; Dahlström U; Echeverria LE; Fang JC; Filippatos G; Fonseca C; Goncalvesova E; Goudev AR; Howlett JG; Lanfear DE; Li J; Lund M; Macdonald P; Mareev V; Momomura SI; O'Meara E; Parkhomenko A; Ponikowski P; Ramires FJA; Serpytis P; Sliwa K; Spinar J; Suter TM; Tomcsanyi J; Vandekerckhove H; Vinereanu D; Voors AA; Yilmaz MB; Zannad F; Sharpsten L; Legg JC; Varin C; Honarpour N; Abbasi SA; Malik FI; Kurtz CE;
    N Engl J Med; 2021 Jan; 384(2):105-116. PubMed ID: 33185990
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dose-dependent augmentation of cardiac systolic function with the selective cardiac myosin activator, omecamtiv mecarbil: a first-in-man study.
    Teerlink JR; Clarke CP; Saikali KG; Lee JH; Chen MM; Escandon RD; Elliott L; Bee R; Habibzadeh MR; Goldman JH; Schiller NB; Malik FI; Wolff AA
    Lancet; 2011 Aug; 378(9792):667-75. PubMed ID: 21856480
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Omecamtiv Mecarbil: A Myosin Motor Activator Agent with Promising Clinical Performance and New in vitro Results.
    Nanasi P; Komaromi I; Gaburjakova M; Almassy J
    Curr Med Chem; 2018; 25(15):1720-1728. PubMed ID: 29278207
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Combined Therapy With Dobutamine and Omecamtiv Mecarbil in Pigs With Ischemic Acute Heart Failure Is Attributed to the Effect of Dobutamine.
    Rødland L; Rønning L; Kildal AB; Myrmel T; How OJ
    J Cardiovasc Pharmacol Ther; 2020 May; 25(3):232-239. PubMed ID: 31645117
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Human Cardiac Ventricular-Like Organoid Chambers and Tissue Strips From Pluripotent Stem Cells as a Two-Tiered Assay for Inotropic Responses.
    Keung W; Chan PKW; Backeris PC; Lee EK; Wong N; Wong AOT; Wong GKY; Chan CWY; Fermini B; Costa KD; Li RA
    Clin Pharmacol Ther; 2019 Aug; 106(2):402-414. PubMed ID: 30723889
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Real-Time Force and Frequency Analysis of Engineered Human Heart Tissue Derived from Induced Pluripotent Stem Cells Using Magnetic Sensing.
    Bielawski KS; Leonard A; Bhandari S; Murry CE; Sniadecki NJ
    Tissue Eng Part C Methods; 2016 Oct; 22(10):932-940. PubMed ID: 27600722
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Frequency-dependent effects of omecamtiv mecarbil on cell shortening of isolated canine ventricular cardiomyocytes.
    Horváth B; Szentandrássy N; Veress R; Almássy J; Magyar J; Bányász T; Tóth A; Papp Z; Nánási PP
    Naunyn Schmiedebergs Arch Pharmacol; 2017 Dec; 390(12):1239-1246. PubMed ID: 28940010
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cardiac Myosin Activators in Systolic Heart Failure: More Friend than Foe?
    Moin DS; Sackheim J; Hamo CE; Butler J
    Curr Cardiol Rep; 2016 Oct; 18(10):100. PubMed ID: 27568794
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Omecamtiv mercabil and blebbistatin modulate cardiac contractility by perturbing the regulatory state of the myosin filament.
    Kampourakis T; Zhang X; Sun YB; Irving M
    J Physiol; 2018 Jan; 596(1):31-46. PubMed ID: 29052230
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A Method for Contraction Force Measurement of hiPSC-Derived Engineered Cardiac Tissues.
    Fujiwara Y; Deguchi K; Miki K; Nishimoto T; Yoshida Y
    Methods Mol Biol; 2021; 2320():171-180. PubMed ID: 34302658
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Direct Myosin Activation by Omecamtiv Mecarbil for Heart Failure with Reduced Ejection Fraction.
    Psotka MA; Teerlink JR
    Handb Exp Pharmacol; 2017; 243():465-490. PubMed ID: 28315072
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.